Skip to main content
Equibles
AXSM logo

AXSM · Axsome Therapeutics, Inc.

Track AXSM — free

Use AXSM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AXSM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$207.15 +1.67 (+0.81%) At close · Aug 26
Market Cap
$10.63B
Shares
52.38M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$207.15 Open$204.48 Day$203.70–210.68 52W close$114.10–255.17 Avg vol 30d687K Short int3.2M · 6.1% float · 4.0d Short vol69% Last earningsAug 10, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 13, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Sell Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 15.2 · calm Equity put/call 0.64
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg +8%
      above
      Price vs 50-day avg −10%
      below
      RSI (14) 38
      neutral
      MACD trend Negative
      52-week position 66%
      mid-range
      Momentum
      relative strength
      Strong
      1-month return −9%
      trailing
      6-month return +28%
      trailing
      YTD return +13%
      this year
      Relative strength +16%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $230 › 200d $192 — 50d above 200d
      Institutional flow Accumulating
      +22% holders QoQ · +138 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.12% of float · ▼ -5.9% MoM · 4.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      506 holders — near 3-yr high, broad support
      Squeeze score 57
      elevated · 0–100
      Fundamentals
      Strong
      EPS growth +39%
      Y/Y
      Free cash flow $-93.9M
      Balance sheet $135.2M
      net cash
      Quant / Vol
      risk profile
      Moderate
      Volatility 43%
      annualized · 1-yr
      Max drawdown −20%
      past year
      ATR 3.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      2 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +8% Bullish
      Price vs 50-day avg
      −10% Bearish
      RSI (14)
      38 Neutral
      MACD trend
      Negative Bearish
      52-week position
      66% Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $230 › 200d $192 — 50d above 200d
      Institutional flow Accumulating
      +22% holders QoQ · +138 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.12% of float · ▼ -5.9% MoM · 4.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      506 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $114 Now $207 · 66% Range high $255
      vs 200-day avg +8% vs 50-day avg -10%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      AUVELITY net product revenue $180.3M 2Q 2026 —
      AUVELITY payer coverage across all channels 89% second quarter of 2026 —
      AUVELITY payer coverage in commercial channel 82% second quarter of 2026 —
      AUVELITY payer coverage in government channel 100% second quarter of 2026 —
      Commercial covered lives (SYMBRAVO) 56% 2Q 2026 —
      Medicare and Medicaid covered lives (SYMBRAVO) 57% 2Q 2026 —
      NBRx growth QoQ 26% 2Q 2026 —
      Patients treated since launch 350,000 2Q 2026 —
      Patients treated since launch (SUNOSI) 109,000 2Q 2026 —
      Patients treated since launch (SYMBRAVO) 19,500 2Q 2026 —
      QoQ growth in activated new writers 21% 2Q 2026 —
      Royalty revenue from Pharmanovia's sales of SUNOSI $1.5M the three months ended June 30, 2026 filing —
      SUNOSI payer coverage across all channels 82% second quarter of 2026 —
      SUNOSI payer coverage in commercial channel 96% second quarter of 2026 —
      SUNOSI payer coverage in government channel 59% second quarter of 2026 —
      SYMBRAVO payer coverage across all channels 57% second quarter of 2026 —
      SYMBRAVO Total covered lives 57% Launch to Date —
      Total covered lives 89% 2Q 2026 —
      Total covered lives (SUNOSI) 82% 2Q 2026 —
      Total covered lives (SYMBRAVO) 57% 2Q 2026 —
      Total Net Product Revenue $218.4M 2Q 2026 —
      TRx in 2Q 2026 266,000 2Q 2026 —
      TRx in 2Q 2026 (SYMBRAVO) 23,500 2Q 2026 —
      Unique writers since launch 69,000 2Q 2026 —
      Unique writers since launch (SUNOSI) 17,000 2Q 2026 —
      Unique writers since launch (SYMBRAVO) 4,700 2Q 2026 —
      AUVELITY first- or second-line use 56% Launch to date —
      AUVELITY monotherapy use 50% Launch to date —
      AUVELITY primary care share of prescribers 35% Launch to date —
      SUNOSI total covered lives 83% Launch to date —
      SYMBRAVO neurologist share of prescribers 60% Launch to date —
      SYMBRAVO new patients since launch 13,500 Launch to date —
      SYMBRAVO sales representatives 150 1Q 2026 —
      AUVELITY net product sales $507.1M full year 2025 —
      SUNOSI net product revenue $124.8M full year 2025 —
      SUNOSI net product sales $120.1M full year 2025 —
      SYMBRAVO net product sales $6.6M full year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AXSM
      Axsome Therapeutics, Inc.
      this stock
      		$10.63B +13.4% +65.5% — 6.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.79B +20.7% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $83.89B +5.6% +20.8% 20.2 2.3%
      ARGX
      Argenx SE
      		 $63.81B +24.5% — — 1.9%
      CSLLY
      Csl Ltd
      		 $60.07B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      506
      % held
      76.3%
      Net QoQ
      +703.9K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      391
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.2M
      Days to cover
      4.0d
      Change
      -201.7K sh
      View
      Short Volume
      Short vol %
      69%
      As of
      Aug 26, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      19
      Value
      $4.4K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      45.8%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Buy
      Member
      Christopher L. Jacobs
      Amount
      $15.0K–$50.0K
      Traded
      Jun 16, 2022
      View
      Financials
      Financials
      Revenue (FY)
      $638.5M
      Net income (FY)
      $-183.2M
      EPS diluted
      $-3.68
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 10, 2026
      This year
      18
      View
      Proposed Sales
      Value
      $71.2K
      Shares
      286
      Filed
      Jun 11, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 10, 2026
      View
      Investor Relations
      Latest news
      Axsome Therapeutics Reports Secon…
      Published
      Aug 10, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      AXSM -5.1% -8.9% +28.3% -5.0% +13.4%
      SPY -0.4% +5.0% +12.4% +2.6% +12.3%
      vs SPY -4.7% -13.9% +15.9% -7.5% +1.1%
      Key facts CIK 1579428 CUSIP 05464T104 13F (30d) 435 filings 433 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)